Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4865528 | 0.89 | MEN1 (0.47) | ALDH1A1MAPTRAB9ALMNASMN1; SMN2 | |
| SCHEMBL4866408 | 0.88 | ALDH1A1 (0.48) | ALDH1A1MAPTRAB9ALMNASMN1; SMN2 | |
| SCHEMBL4871242 | 0.85 | PTGS1 (0.42) | ALDH1A1LMNASMN1; SMN2HTTKMT2A | |
| SCHEMBL4866923 | 0.85 | NPC1 (0.42) | ALDH1A1MAPTRAB9ALMNASMN1; SMN2 | |
| SCHEMBL4873322 | 0.81 | SMN1; SMN2 (0.43) | ALDH1A1MAPTRAB9ALMNASMN1; SMN2 | |
| SCHEMBL4870542 | 0.81 | LMNA (0.42) | ALDH1A1MAPTLMNASMN1; SMN2HTT | |
| SCHEMBL4866826 | 0.80 | MAPT (0.42) | ALDH1A1MAPTRAB9ALMNASMN1; SMN2 | |
| SCHEMBL4866793 | 0.77 | KMT2A (0.44) | ALDH1A1MAPTCYP3A4CYP2C9MEN1 | |
| SCHEMBL4876301 | 0.77 | KMT2A (0.47) | ALDH1A1MAPTNPC1CYP3A4CYP2C9 | |
| SCHEMBL4870570 | 0.76 | ALDH1A1 (0.44) | ALDH1A1MAPTRAB9ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323478-B2 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION (US) | 2008-01-29 | — | — | US | claimed |
| US-20040229883-A1 | Melanin concentrating hormone receptor ligands | BAKTHAVATCHALAM RAJAGOPAL (US) | 2004-11-18 | — | — | US | claimed |
| US-20030191136-A1 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION | 2003-10-09 | — | — | US | claimed |
| US-6569861-B2 | Phenylcycloalkylmethylamino and phenylalkenylamino derivatives, including 1-phenyl-2-aminomethylcyclopropanes; treatment of a variety of metabolic, feeding, and sexual disorders including obesity. | NEUROGEN CORPORATION | 2003-05-27 | — | — | US | claimed |
| US-20020052383-A1 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION | 2002-05-02 | — | — | US | claimed |
| US-7323478-B2 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION (US) | 2008-01-29 | — | — | US | disclosed |
| US-20040229883-A1 | Melanin concentrating hormone receptor ligands | BAKTHAVATCHALAM RAJAGOPAL (US) | 2004-11-18 | — | — | US | disclosed |
| US-6753336-B2 | EATING DISORDERS; SEXUAL DISORDERS | NEUROGEN CORPORATION | 2004-06-22 | — | — | US | disclosed |
| EP-1366030-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS | Neurogen Corporation (US) | 2003-12-03 | — | — | EP | disclosed |
| US-20030191136-A1 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION | 2003-10-09 | — | — | US | disclosed |
| US-6569861-B2 | Phenylcycloalkylmethylamino and phenylalkenylamino derivatives, including 1-phenyl-2-aminomethylcyclopropanes; treatment of a variety of metabolic, feeding, and sexual disorders including obesity. | NEUROGEN CORPORATION | 2003-05-27 | — | — | US | disclosed |
| US-20020052383-A1 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION | 2002-05-02 | — | — | US | disclosed |
| WO-2002004433-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229883-A1 | Melanin concentrating hormone receptor ligands | MCHR1, NPY1R, MCHR2 | ALDH1A1 1711/4885MAPT 2762/4885RAB9A 202/4885 |
| US-20020052383-A1 | Melanin concentrating hormone receptor ligands | MCHR1, NPY1R, MCHR2 | ALDH1A1 1644/4885MAPT 2821/4885RAB9A 184/4885 |
| US-20030191136-A1 | Melanin concentrating hormone receptor ligands | MCHR1, NPY1R, MCHR2 | ALDH1A1 1711/4885MAPT 2762/4885RAB9A 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.